Amantadine does not modulate reinforcing, subjective, or cardiovascular effects of cocaine in humans

Pharmacology Biochemistry and Behavior

Volumn 76, Issue 3-4, 2003, Pages 401-407

  Collins, Eric D ^a   Vosburg, Suzanne K ^b   Hart, Carl L ^b   Haney, Margaret ^b   Foltin, Richard W ^b  

^a Columbia University ^*  (United States)

^b NONE

Author keywords

Amantadine; Cardiovascular effects; Cocaine; Dopamine; Human; NMDA antagonists; Self administration; Subjective effects

Indexed keywords

AMANTADINE; COCAINE;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG SELF ADMINISTRATION; FEMALE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MAINTENANCE THERAPY; MALE; MEDICAL LITERATURE; PHYSIOLOGY; PRIORITY JOURNAL; SMOKING;

EID: 0344845095     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2003.08.013     Document Type: Article

References (40)

1. Alterman A.I., Droba M., Antelo R.E., Cornish J.W., Sweeney K.K., Parikh G.A.et al. Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend. 31:1992;19-29.
2. Balster R.L., Chait L.D. The effects of phencyclidine on amphetamine stereotypy in rats. Eur. J. Pharmacol. 48:1978;445-450.
3. Butzer J.F., Silver D.E., Sahs A.L. Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology. 25:1975;603-606.
4. Collins E.D., Ward A.S., McDowell D.M., Foltin R.W., Fischman M.W. The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans. Behav. Pharmacol. 9:1998;587-598.
5. Damianopoulos E.N., Carey R.J. Evidence for N-methyl-D-aspartate receptor mediation of cocaine induced corticosterone release and cocaine conditioned stimulant effects. Behav. Brain Res. 68:1995;219-228.
6. Fischman M.W., Foltin R.W., Nestadt G., Pearlson G.D. Effects of desipramine maintenance on cocaine self-administration by humans. J. Pharmacol. Exp. Ther. 253:1990;760-770.
7. Foltin R.W., Fischman M.W. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans. J. Pharmacol. Exp. Ther. 278:1996;1153-1164.
8. Foltin R.W., Fischman M.W., Nestadt G., Stromberger H., Cornell E.E., Pearlson G.D. Demonstration of naturalistic methods for cocaine smoking by human volunteers. Drug Alcohol Depend. 26:1990;145-154.
9. Foltin R.W., Fischman M.W., Levin F.R. Cardiovascular effects of cocaine in humans: laboratory studies. Drug Alcohol Depend. 37:1995;193-210.
10. Gawin F.H., Morgan C., Kosten T.R., Kleber H.D. Double-blind evaluation of the effect of acute amantadine on cocaine craving. Psychopharmacology. 97:1989;402-403.
11. Giannini A.J., Folts D.J., Feather J.N., Sullivan B.S. Bromocriptine and amantadine in cocaine detoxification. Psychiatry Res. 29:1989;11-16.
12. Gianutsos G., Chute S., Dunn J.P. Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur. J. Pharmacol. 110:1985;357-361.
13. Handelsman L., Limpitlaw L., Williams D., Schmeidler J., Paris P., Stimmel B. Amantadine does not reduce cocaine use or craving in cocaine-dependent methadone maintenance patients. Drug Alcohol Depend. 39:1995;173-180.
14. Haney M., Foltin R.W., Fischman M.W. Effects of pergolide on intravenous cocaine self-administration in men and women. Psychopharmacology (Berl.). 137:1998;15-24.
15. Haney M., Collins E.D., Ward A.S., Foltin R.W., Fischman M.W. Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacology (Berl.). 143:1999;102-110.
16. Holmberg S., Serzysko W., Varnauskas E. Coronary circulation during heavy exercise in control subjects and patients with coronary heart disease. Acta Med. Scand. 190:1971;465-480.
17. Kampman K., Volpicelli J.R., Alterman A., Cornish J., Weinrieb R., Epperson L.et al. Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. Drug Alcohol Depend. 41:1996;25-33.
18. Kampman K.M., Volpicelli J.R., Alterman A.I., Cornish J., O'Brien C.P. Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. Am. J. Psychiatry. 157:2000;2052-2054.
19. King G.R., Joyner C., Ellinwood E.H. Jr. Continuous or intermittent cocaine administration: effects of amantadine treatment during withdrawal. Pharmacol. Biochem. Behav. 47:1994;451-457.
20. Kitamura K., Jorgensen C.R., Gobel F.L., Taylor H.L., Wang Y. Hemodynamic correlates of myocardial oxygen consumption during upright exercise. J. Appl. Physiol. 32:1972;516-522.
21. Kolar A.F., Brown B.S., Weddington W.W., Haertzen C.C., Michaelson B.S., Jaffe J.H. Treatment of cocaine dependence in methadone maintenance clients: a pilot study comparing the efficacy of desipramine and amantadine. Int. J. Addict. 27:1992;849-868.
22. Kornhuber J., Weller M., Schoppmeyer K., Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J. Neural. Transm. Suppl. 43:1994;91-104.
23. Kosten T.R., Morgan C.M., Falcione J., Schottenfeld R.S. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch. Gen. Psychiatry. 49:1992;894-898.
24. Leal J., Ziedonis D., Kosten T. Antisocial personality disorder as a prognostic factor for pharmacotherapy of cocaine dependence. Drug Alcohol Depend. 35:1994;31-35.
25. Malcolm R., Herron J., Sutherland S.E., Brady K.T. Adverse outcomes in a controlled trial of pergolide for cocaine dependence. J. Addict. Dis. 20:2001;81-92.
26. Matsumoto R.R., Brackett R.L., Kanthasamy A.G. Novel NMDA/glycine site antagonists attenuate cocaine-induced behavioral toxicity. Eur. J. Pharmacol. 338:1997;233-242.
27. Oliveto A., Kosten T.R., Schottenfeld R., Falcioni J., Ziedonis D. Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. J. Subst. Abuse Treat. 12:1995;423-428.
28. Peeters M., Maloteaux J.M., Hermans E. Distinct effects of amantadine and memantine on dopaminergic transmission in the rat striatum. Neurosci. Lett. 343:2003;205-209.
29. Pierce R.C., Meil W.M., Kalivas P.W. The NMDA antagonist, dizocilpine, enhances cocaine reinforcement without influencing mesoaccumbens dopamine transmission. Psychopharmacology (Berl.). 133:1997;188-195.
30. Pulvirenti L., Balducci C., Koob G.F. Dextromethorphan reduces intravenous cocaine self-administration in the rat. Eur. J. Pharmacol. 321:1997;279-283.
31. Ranaldi R., French E., Roberts D.C. Systemic pretreatment with MK-801 (dizocilpine) increases breaking points for self-administration of cocaine on a progressive-ratio schedule in rats. Psychopharmacology (Berl.). 128:1996;83-88.
32. Ranaldi R., Bauco P., Wise R.A. Synergistic effects of cocaine and dizocilpine (MK-801) on brain stimulation reward. Brain Res. 760:1997;231-237.
33. Robbins S.J., Ehrman R.N., Childress A.R., O'Brien C.P. Using cue reactivity to screen medication for cocaine abuse: a test of amantadine hydrochloride. Addict. Behav. 17:1992;491-499.
34. Sannerud C.A., Griffiths R.R. Amantadine: evaluation of reinforcing properties and effect on cocaine self-injection in baboons. Drug Alcohol Depend. 21:1988;195-202.
35. Shoptaw S., Kintaudi P.C., Charuvastra C., Ling W. A screening trial of amantadine as a medication for cocaine dependence. Drug Alcohol Depend. 66:2002;217-224.
36. Tennant F.S. Jr., Sagherian A.A. Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. Arch. Intern. Med. 147:1987;109-112.
37. Walsh S.L., Preston K.L., Sullivan J.T., Fromme R., Bigelow G.E. Fluoxetine alters the effects of intravenous cocaine in humans. J. Clin. Psychopharmacol. 14:1994;396-407.
38. Weddington W.W. Jr., Brown B.S., Haertzen C.A., Hess J.M., Mahaffey J.R., Kolar A.F.et al. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am. J. Drug Alcohol Abuse. 17:1991;137-152.
39. Witkin J.M. Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists. Life Sci. 53:1993;PL405-PL410.
40. Ziedonis D.M., Kosten T.R. Pharmacotherapy improves treatment outcome in depressed cocaine addicts. J. Psychoactive Drugs. 23:1991;417-425.